Forendo Pharma Oy

Organon head of research and development Sandra Milligan is optimistic about the road ahead in women’s health, but also believes changes are needed in investment, research and regulation to smooth th

Two new venture capital funds were announced a day apart during the last week of June, each with $200m to fund early-stage biotechnology companies, though only one is exclusively focused on drug devel

Organon & Co. CEO Kevin Ali is the first to admit that the company faced a lot of skepticism when it spun out of Merck & Co., Inc. with three seemingly disparate sets of assets – established produc

Rising Leaders Home The biotech bubble bursting has created more affordable options for the corporate venture capital (VC) arms of major pharma companies to provide support to innovative start-ups in